are With Officer Medical Celsion’s Jeffrey Chief our Officer; Nicholas you thanks for Financial Thank you, Jeff. Borys, morning, Good joining Dr. whom heard. Chief today’s Church, just and call. from and me everyone,
following we continue not by be with we fundamentals to pleased questions. the meet have could this to expect we our with morning that sound to prepared more our you update on of very great opportunity a cash saying progress objectives start we and your a I confidence. on always, company the pleased is to to want report to our the position are deal and and solid frankly remarks As that answer
think safe for And say those is I goals have that you made our Celsion following steady that ends. been us, and towards that to progress it's consistent know well-positioned. demonstrable we been who have have those and
I inflection two value our three X, that portion we HCC and developments. a key are news X including an committed data trial of worth and analysis Number to and utilization would timely repeating focus which cash a from with two milestones. said focused strategy ovarian strong last efficient points, And phase cash would we providing call X ensure plans in shareholder phase company in Our development financing on to achievement steady study number operationally in a flow a quarterly we maintain runway balance is again one, conference during our enhancing committed phase our of tight that cancer. from critical to sheet cash maintain this number
our accomplishments. misdirected. me to let our life expenses objectives With So quarter you to you be don’t translate into second for want I these real regards
in I of more. line requires that our enhance spending with clearly spending with on our and our million out on GAAP want the Celsion line happen the first announcement. sight a in diagnosed soon, focus, section tight and not will quarter primary Phase interim Based and burden expenses will will ThermoDox analysis glide our discuss on of cash operating analysis risk X our is We want efficacy study see I OPTIMA late option XXX point over patient global next line budgets accounting with this of newly of to we in the the financial earnings in enrollment second noncash it’s to to to But stock our preplanned the path is in that spending a this us completion say to liver cash expenses. Jeff putting $X.X today's trial the on expect study is of of enrollment data. expenses cancer year.
from We in the about assist talk detail consultants expect important the it’s drafting the definitive ThermoDox with Celsion prognostic that NDA, at some script. not and nonetheless, treatment, too this Anticipated analysis not later to in we'll will be that first successor directionally quotes soon start. to
door to XX the see to to from experience process submit XX time the to a the month that Our when the of an we FDA. this initiation door project we suggests is data positive application
very three do work China. and seen than for survival and suggested fast-track two lot our lower does; pathways to to success surprising different this And said appears to this commercial as six Europe versus overall percentages that’s have by bar you the survival a again blockbuster a for further month the also that FDA, would guaranteed early and year regards of and from directly regulatory data, agency an study we and for acceptable a was the rather China rates will three planet provide would begun with potentially in this review optimized China overall have survival derisking study. with the development from deal surprise. person overall we be to with threshold As a in and year in more as ThermoDox we we heat a the a attention. measure. FDA the but finally survival position it the endpoint; Quite response And we was what the work They that grant the our on reconfirmed ThermoDox ThermoDox in we I we’ve primary development any CFDA, great survival a is is largest met approval the our but see market standard positive data. reset will suggests one, U.S., China; that for the month last The following of important opportunity ensure all the continue of that process can filed re-validating keep posted or deserves potential NDA be FDA, the
Now the II we’ve for two study; initiated phase our on clinical open IL-XX study label XXX four Gen-X, the patients. sites in newly our advanced X, cancer randomized subject ovarian the of of X OVATION Gen-X immunotherapy, gene-mediated phase X diagnosed
remains initial X the We year. and patient for phase end expect to goal now complete before the the that we anytime as announce therapeutic first the arm enrollment of our unchanged
tight line So you can see our with focus. achievement milestones is in development of
net XXXX possible. two million quarters to most only of behind we balance balance I X, operating venture added two strategy sheet for point quarter maintaining shareholders’ phase We our first Jersey of our Optima the see low In June on proprietary big well with X programs are well it's run you XXXX. And applied us. and interest continue strong in in expect programs taking note X New a committed one ways a focused clear value, and implemented. worth XXXX, is hope if to see the should fourth will the be operating we year our losses into can at for is with you Horizon a our meaningful years quarters I very fully a and of OVATION results good $XX the of last being announce phase the four sheet announced June also of trust rate the advances, that the three our ThermoDox from strong company approved to add sale general the for and the which loan recently each can study balance to in news X deal flow Also operating which over these and and study non-dilutive is runway cost shareholders. for have we another steady of that
are to not believe achieved. work so in new to Both the Celsion's for combination for be chance now therapy platform outcomes to designed we treatment immuno story with patients about So but Celsion in of naïve are what to oncology. change platforms the based, meaningful the the stage, best proposition. of chance outcome both populations standard unmet with talk clinically indications market meaningful need and clinical us the like provide particularly a maybe the the chemo and cancer of future extraordinary those an will one care, technologies are two approach and therapy I and ontology an value evaluated adoption and of diagnosed are of has we in legacy unique successful, this amount newly power one for being Both rapid pricing if high would penetration. small potential who nanoparticle
University Duke applications the form that When hold Our invented technology heated in relations. with is encourage to and evidence its please information been would all incontrovertible, body refer of first with can the heat lysolipid are chemotherapeutics. temperature, in publications all thermally liposomes, with if local technology rapidly them at sensitive medical works is need in loaded to that's liposomal sensitive above in administered to that a I be exclusive meets range the the you a that's releases with the payload current call it XX°C investor tissue regard be vessel liposome That above concentration. platform its ESL technology just We proprietary you license our manuscripts our replete high engineered of and it's check intravenously. to we
virtually ThermoDox has called every is formulation antibiotic being agency and doxorubicin, in worldwide. the drug implies broad-spectrum ThermoDox a approved applied among first cancers liver a of name regulatory heat breast shown others. Our activity is both conditionally by and is as name sensitive liposomal the form that
is HCC as cancer. primary Our carcinoma or it's also lead cellular hepatic ThermoDox for indication liver known
prior on than study years In lesions a and XXX survival for arm months. treatment control of That’s from curative in with models, heating the and annually for years followed that with tested when with this been need analysis XX% centimeter and ThermoDox XXX RFA two and survival used be RFA driven correctly treating being this ThermoDox. And the cover timing. peer-reviewed manuscripts OPTIMA we’ve Research is Plus computational techniques better many X years X about every survival on a is reached think radiofrequency I’ll understanding time in sized median XX to after minutes repeating. as minutes the over death evaluated observations in aspect never many difficult thesis more conference based I dose ThermoDox single minimum design XX combination analyses the was is for population Cancer the X.X for addition and earlier and heat time when be my medical administered Clinical cancer, is application bears our tumors cases the supporting death. was death the data that and study is the cure in this cancer. Journal again RFA journals optima was impact combined of in HCC arrived group group, protocol XXX,XXX liver that supporting major fully overall has markets our OPTIMA properly quarter final refinement in conducted that’s been than evaluate the study colleagues. overwhelming and a entire this and and XX of although prior RFA every globally; of hepatocellular of potential the will unmet patient for period. a we potential the has now to XX the we in study The to with the the but being primary of rate in call very present this of our detect problem. is improving evidence word of historically countries from and some our them XX% our and repetitive study our for this reported a journals in the word XX in in significant their not basis powered multiple oncology months, trial global ablation, phase in by is what That new it again investigators say with form where at Optima Median that’s prospective the of readout are ThermoDox in time study X.X Optima a published of talked including study’s the than that subgroup risk carcinoma believe of population this for patient in more largest RFA virtually they best study larger zones the to the survival that I XX for fact has reduction research Based intermediate used studies is for thesis all With Hypothermia. data its X refinement preclinical using to
as other saw important for we to RFA the blinded with of I to duration can effective lesion conclusion free that RFA in the combined important Independent finding the HCC. extremely the from RF request just want population is time. view last intent study results again once that is in the the XX% analysis see We the had also in the can compliance study. subgroup Committee from Health an intent showed each declared you and is and ablation, believe concluded for in true April single to remind XXX about among performance far NIH Data millions drawn of trends of progression interesting single lesion of survival the terabytes is effective, benefit point that provided met of HEAT the alone. aspect some with RFA data that we reported longer specifically, millions protocol HEAT with last data Intervention patients, population site emphasize that learned subgroup NIH the independent in found statistically significant study, be and at that patients which from treating heating very continue I addition, study, the treat same want the of analysis subgroup be the consistent quality conducted be XXX the our Monitoring X an to at XXX in previously better to of in that survival. to things, in that the very this study the compliance ThermoDox The call, they definitive review no encouraging Director DMC independently Institutes HEAT that over heating I So news PFS to nonetheless example, study. to The X when Oncology study improvement sight quarterly longer to a blinded we that’s National it’s review, ThermoDox's the so of minimum with slice ThermoDox we a not overall population RFA talked OPTIMA same we at presented conducted by this looked The treat importantly, the slightly to the is that we not at for than patients compliance of
of of statistically with were the survival. of North University ThermoDox in treatment heating I use only patients trial focused body’s evidence Oncology. is many radiologists Lancet more. sufficient a safety known last you patient focused tissues, Oxford trial team and X in ThermoDox ThermoDox, successfully from that findings another December notice efficacy The technique Adding of importance room The cancers. along evaluated to ultrasound published XX some there’s presented combined to crowd the noninvasive trial heat with the trial procedure peer-reviewed in was significant also in at of the so to delivery the by to longer the is ThermoDox just RSNA, Hyfuels to doxorubicin means of phase show Oxford of may energy overall Kingdom. up think for acoustic conducted delivery tenfold evidence ThermoDox of focused at have tumors increased five team heating that’s that liver ThermoDox a the month at multidisciplinary anesthesiologists method as phase standing this ultrasound study of clear. Society phase We the ultrasound to results XXXX. time the were The United journal This oncologists, improvement are engineers, a in X to medical of and the in These the supporting Radiological of And America Conference
front Europe, note all in and regulatory things priority ThermoDox the exclusivity Korea, in and and South to the and enroll remind the the Canada, granted China, country has launch US also America US, Optima primary and seven reviewed that Thailand, for and designation among Taiwan and our of the designation markets, the ThermoDox major and XX will I and filings Optima agencies received Philippines, to regulatory have other On across including each liver protocol. HCC the number based study the strategy Vietnam in from fast-track support Malaysia extends I study XX Europe, from provides registrational review. has been for the is Asia these we that cancer designed for both orphan which North respectively in market US globe interactions markets. Europe, these years you on a major market patients sufficient regulatory approved
pleased on goal have class course we the I’m world quality high is research management and analytics. data side recognized ICH protocol report execution contract Of compliance, is and important clinical adherence organizations teams. extremely good to ensure that and internationally practice, data to engaged execution The
with price We All organizations. capable world. are are commercial and us once also a high producing ThermoDox proven basis would providing of blended a the have chain I And manufacturing say all margins three registered reliable very with regions of form. in we gross supply and redundant respectable contract
now I guidance. referred give earlier as some to to analyses you would the So interim like I
know, expect as out to you pencil, pull data. complete been on with will enrollment and path two So study be preplanned shortly I interim The if analyses. which said, the a have said glide we has it study Optima your after we designed efficacy as to have you
will deaths and at The deaths, needed the XXX deaths. occur analysis XXX XXX final at first if at the second
of XX% X.XX for most in the the death the study put the stent hazard that for for with demonstrated that So our the you, ratio for heat therapeutic statisticians the this in in the I'm going PE I ratio to risk plan a been has want subgroup, study translate you, for that's Optima all but so us to not perspective a basis are arm, X.XXX hazard the basis. represents to reduction equal .XX of group
analysis that’s at first death, to for from reduction this it point. ratio risk of Results will will for this are analysis analysis Now that Optima if begin in study at we next or successful X.XX, we now to on interim the final preplanning track most a the the likely a XX% not hazard bar. are probably at interim other In than and definitive. high that converts a demonstrates analysis point know be success efficacy prognostic to words,
almost that have X.XX on needed XX% sorry The deemed lower better deemed which the success for hazard death. it XX% with successful the or which it we if -- I translates likely reduction, and for in X.X the to final much death. by was appears point. if the XX% based. The final second XX% in subgroup of risk chance will a plan When interim am bar successful much in analysis, XX% risk to talking improvement cover the to ratio of compared analysis sale, all should reduction be at at demonstrates have for And be about we efficacy analysis been XXXX approved analysis. cash a a NOLs ratio be hazard our success will needed, the reduction we’ve HEAT for of for or will that point X.X sufficient point this which at which are if study late of
next making positioned great see, the was I progress two of I where can is and So, coming deal conversation, is for you well think the a started years. the -- think company this positioned I well-positioned
cases year annually new HCC want to incidents opportunity the worldwide, XXXX most for opportunity. cancers our indicated for that's is ThermoDox and ladies death XX% period the over a over rate problem liver the conclude conservatively United if liver incidence discussion the the of Center talked gentlemen XXXX. this successful one HCC since States new not patients growing that sincerely. be from I OPTIMA that in commercial about X% and over if drugs XXX,XXX our in lifetime HCC a market to we’re each increased the So and and The is the annually cancer important believe reports in This it HCC on oncology ThermoDox of is from with rates Control with CDC, the of global the I recent generation of Disease addressable basis that XXXX ThermoDox and cases is new before at We’ve XXX,XXX intermediate and grossed the XX% stage right with study will of
development to in proprietary gears Gen-X and localized ovarian of shifting treatment our cancer. therapy gene advanced Now for
discussed in recruits the last to our As system Gen-X I that's the TheraPlas which technology a immune platform fight malignancies. on call immunotherapy, developed novel
that’s cavity administered IL-XX Gen-X’s is Our proprietary protein a DNA a delivery plasmid cavity, invade for tumor incorporated into cytokine, agent body nanoparticle little by cavity locally up incorporated that a created our cell’s the DNA’s cells coded of the take peritoneum bladder machinery, or the strand plasmid active is or vector, to days peritoneum a anticancer the interlukin-XX inflammatory removal mass, an a production nanoparticles into IL-XX, over is each potent and when of surgical into or a biopharmacy -- synthetic IL-XX surrounding metabolic sustained these even the seven protein. the like turning for
The GEN-X is are studying we first cancer. for ovarian in indication
with chance patients newly surviving years. For this a five there’s of XX% cancer this less than cancer diagnosed --
drying scientific and advanced GEN spreads this previous of four stage been you. of the either patients. clinical the X that trial to chemotherapy treatment cycles is throughout but has activity GEN study, up weekly dose clinical for followed newly combination one or the it's however, cancer this promising with the I improve neoadjuvant X chemotherapy is trials X. shown clearly naïve GEN the diagnosis escalation we in tumor as goal the outcome chemotherapy added in study three debulking population surgery pelvis The when you masses neoadjuvant patients importantly, and to with phase GEN made Ovation interval In have evaluated recently major I eight accompanied the demonstrated known most completed. want by One will and stages the this patient three of the four in X by study disease remind neoadjuvant region. chemotherapy as when our to plus surgical data and some cytis. over In is Study benefit used shrinking monotherapy fluids has in go reasons most a the the in from of diagnosed results, ovation Ib
the Now are and are small nonetheless. the impressive finding findings but folks, these number
few compelling go you. in XX clear DSMB over dose with complete all demonstrated that's of The evidence points in signals. our up neoadjuvant is dependent numbers, surgeons a surgeons oversight bioactivity are PIs I partial did and and plus limiting GenX clinical is evidence efficacy in included The bullet significant As toxicities per of findings Investigators milligrams patients one. and surgeons. are OB/GYN chemotherapy impressive. a find no but not XX% meter There to small of and any safe this the response dose committee, toxicities study squared. in directionally associated with Gen
in about November And a per tumor the the these to Based dose XX the on RX is We’re in we XX the protocol This is X the at an phase Historically, of at X for trial the quarters an This resection six because able two localized label meeting. the reached called talked patients subjects, the be per XXX of improve phase population by meter treat criteria appear XXX% X XX to months. either projected same treatment continuation open at ovation is completely and to prior in will GEN XX% for outcome as and the with up we treated a announced from a highest is a followed important square patients The it's still to ovation entry arm about since remove X cancer. X, for or are months the patients. major all disease meter study this prior reported in of our this higher XX, be dose to selected protocol subjects. clinical be logical first the in at treatment can study pro concluded in the PFS is mg surrogate haven't PFS which in equates submission per micro in local And phase FDA than and an survival. definitive GEN important. and RX milligram visible of study changes one at tumor to in survival. this treated we is findings XXX XXX the ovarian square, addition. environment clear protocol one randomized overall dose of XB immune the PFS the now the we patient study three the over called
that continue therapeutic arm So by receive to plus to followed patients be the Gen patients in with a neoadjuvant treated treatment. chemotherapy you know surgery X GEN-X, surgery additional to will of are up following doses maintenance nine intraperitoneal
surrogate may Our stimulation survival. a for after surgery of hypothesis system a is the by further which is that continuous immune provide benefit delaying progression again improved know we
we’ll in that have those about on non-technically to negotiate track on planned sites behind for all have and delays will four three XXXX. we August; quarter of timing, optimistic study two up of make portion the sites to the initiate randomized X have a add all have originally total and want few by now catch had remain in ovation two we lost phase costs, religious functioning in expect more to be how the of X clinical I you negotiations as that frankly we now and X up we we our effort most give to hard, second the of an expected controlling a to costs Phase most September, study; related update are Now for we six are us; to administratively, we
focused report study XXXX. label we we. as be are on is everyone will open know data This I periodically and importantly Now an throughout will data
this at protocol strong, to of I expect with discuss continue our I more look patients data follow But treated plan per for to final we assuming more on back of we FDA, remains optimistic half options study the accelerating from designation, later. for the review the breakthrough I the within to that a the study we second PFS become. our Going data year, OVATION PFS the OVATION the and I currently program including
forward and initial very -- we’re readouts in the one I by we’re in OVATION both Gen-X’s the II the in initial sorry So data initiation to OVATION coming looking in PFS I early the -- II excited the OVATION prospects months. final am
conclude saying milestones to like to And clinical resources prudent turn to the to with Jeff? important to financials goals. delivering over financial Jeffrey our I’d want management financial I are development of on and by the multiple well-positioned the forward plans achieve over we Church. we’re achieving looking and backed our year the discuss call remainder by operational now So to